These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37403288)

  • 41. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR).
    Godesi S; Lee J; Nada H; Quan G; Elkamhawy A; Choi Y; Lee K
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovering potential inhibitors of Raf proto-oncogene serine/threonine kinase 1: a virtual screening approach towards anticancer drug development.
    Khan A; Bealy MA; Alharbi B; Khan S; Alharethi SH; Al-Soud WA; Mohammad T; Hassan MI; Alshammari N; Ahmed Al-Keridis L
    J Biomol Struct Dyn; 2024; 42(4):1846-1857. PubMed ID: 37104027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-based de novo design and identification of D816V mutant-selective c-KIT inhibitors.
    Park H; Lee S; Lee S; Hong S
    Org Biomol Chem; 2014 Jul; 12(26):4644-55. PubMed ID: 24853767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A virtual screening investigation to identify bioactive natural compounds as potential inhibitors of cyclin-dependent kinase 9.
    Atiya A; Shahidi H; Mohammad T; Sharaf SE; Abdulmonem WA; Ashraf GM; Elasbali AM; Alharethi SH; Alhumaydhi FA; Baeesa SS; Rehan M; Shamsi A; Shahwan M
    J Biomol Struct Dyn; 2023 Nov; 41(19):10202-10213. PubMed ID: 36562191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The human tyrosine kinase Kit and its gatekeeper mutant T670I, show different kinetic properties: Implications for drug design.
    Kissova M; Maga G; Crespan E
    Bioorg Med Chem; 2016 Oct; 24(19):4555-4562. PubMed ID: 27527414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of high-affinity pyridoxal kinase inhibitors targeting cancer therapy: an integrated docking and molecular dynamics simulation approach.
    Banerjee P; Chandra A; Mohammad T; Singh N; Hassan MI; Qamar I
    J Biomol Struct Dyn; 2024 Oct; 42(16):8523-8540. PubMed ID: 37578056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovering Gummadiol and Isoarboreol as potential inhibitors of sphingosine kinase 1: virtual screening and MD simulation studies.
    Elasbali AM; Al-Soud WA; Alhassan HH; Mousa Elayyan AE; Kamal M; Alanazi H; Alharbi B; Alharethi SH; Mohamed BM
    J Biomol Struct Dyn; 2023; 41(22):12789-12797. PubMed ID: 36644886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of ( E)- N
    Liu X; Wang B; Chen C; Qi Z; Zou F; Wang J; Hu C; Wang A; Ge J; Liu Q; Yu K; Hu Z; Jiang Z; Wang W; Wang L; Wang W; Ren T; Bai M; Liu Q; Liu J
    J Med Chem; 2019 May; 62(10):5006-5024. PubMed ID: 31046271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
    Roy T; Boateng ST; Banang-Mbeumi S; Singh PK; Basnet P; Chamcheu RN; Ladu F; Chauvin I; Spiegelman VS; Hill RA; Kousoulas KG; Nagalo BM; Walker AL; Fotie J; Murru S; Sechi M; Chamcheu JC
    Bioorg Chem; 2021 Feb; 107():104595. PubMed ID: 33450548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia.
    Parcha P; Sarvagalla S; Madhuri B; Pajaniradje S; Baskaran V; Coumar MS; Rajasekaran B
    Chem Biol Drug Des; 2017 Oct; 90(4):596-608. PubMed ID: 28338290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.
    Ye Q; Fu C; Li J
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
    Shafique S; Bibi N; Rashid S
    J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview.
    Sartini S; Dario B; Morelli M; Da Settimo F; La Motta C
    Curr Med Chem; 2011; 18(19):2893-903. PubMed ID: 21651490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
    Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
    Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.